Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL357639 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL3644995 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL29250215 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| D-Histidine SCHEMBL3639231 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL31618930 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL5134199 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL3154317 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL16893960 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| D-Histidine SCHEMBL8002459 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL209484 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015429-A1 | Method for Producing Spesolimab | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-4673564-A1 | DEVELOPMENT OF CELL MEDIUM AND FEED ON MAMMALIAN CELLS | Evonik Operations GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12448456-B2 | Method for producing spesolimab | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-10-21 | — | — | US | disclosed |
| CN-114807010-B | Cell culture medium | 勃林格殷格翰国际公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024180052-A1 | DEVELOPMENT OF CELL MEDIUM AND FEED ON MAMMALIAN CELLS | EVONIK OPERATIONS GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| EP-4334356-A1 | METHOD FOR PRODUCING SPESOLIMAB | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117222668-A | Method for preparing SPESOLIMAB | 勃林格殷格翰国际有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230203449-A1 | CELL CULTURE MEDIUM | BOEHRINGER INGELHEIM INT (DE) | 2023-06-29 | — | — | US | disclosed |
| EP-3736326-B1 | CELL CULTURE MEDIUM | BOEHRINGER INGELHEIM INT (DE) | 2023-05-10 | — | — | EP | disclosed |
| US-11505784-B2 | Cell culture medium | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-22 | — | — | US | disclosed |
| US-20060223147-A1 | Process for producing glycoprotein composition | KYOWA HAKKO KOGYO CO., LTD., (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1705251-A1 | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
| EP-1686173-A1 | GENOMICALLY MODIFIED CELL NEUTRALIZED TO SERUM-FREE SYSTEM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-08-02 | — | — | EP | disclosed |
| EP-1676860-A1 | PROCESS FOR PRODUCING ANTITHROMBIN III COMPOSITION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-07-05 | — | — | EP | disclosed |
| EP-1676910-A1 | GENOMICALLY MODIFIED CELL | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-07-05 | — | — | EP | disclosed |
| US-20060024793-A1 | Method of producing recombinant antithrombin III composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-02 | — | — | US | disclosed |
| US-20060021071-A1 | Cell in which genome is modified | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050175599-A1 | Process for producing substance | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1449919-A1 | PROCESS FOR PRODUCING SUBSTANCE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-1229125-A1 | PROCESS FOR PRODUCING POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223147-A1 | Process for producing glycoprotein composition | UGGT1, FUCA1, ENGASE | HRH3 4819/4885GLA 193/4885CYP3A4 3640/4885 |
| US-20060024793-A1 | Method of producing recombinant antithrombin III composition | SERPINC1, F13B, F13A1 | HRH3 3207/4885GLA 219/4885CYP3A4 4077/4885 |
| US-20260015429-A1 | Method for Producing Spesolimab | IL36G, IL15RA, IGF2R | HRH3 1602/4885GLA 3187/4885CYP3A4 4028/4885 |
| US-20060021071-A1 | Cell in which genome is modified | UGGT1, GPI, ENGASE | HRH3 4828/4885GLA 91/4885CYP3A4 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.